NCT06481098

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15275 in Healthy and Obese Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 74 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This Study is a Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15275 in Healthy and Obese Subjects.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	HM15275	HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.
DRUG	Placebo of HM15275	A sterile, matching solution supplied in pre-filled syringes.

Timeline

• Start date: 2024-05-28
• Primary completion: 2025-05-02
• Completion: 2025-05-02
• First posted: 2024-07-01
• Last updated: 2025-05-22

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study